Dual approach of Vectorized gene therapy along with Vectorized antibodies

Revolutionizing Treatment for Neurodegenerative Diseases and Beyond
The promise of vectorized gene therapy has ignited a beacon of hope for individuals battling debilitating central nervous system (CNS) proteinopathies and rare neurological diseases. Our groundbreaking pipeline, spearheaded by state-of-the-art vectorized gene therapy, is poised to halt disease progression and restore function in patients grappling with some of the most challenging diseases and conditions to treat.
At the forefront of our efforts lies Parkinson's disease, a neurodegenerative disorder characterized by the accumulation of misfolded alpha-synuclein protein and Alzheimer Diseases characterized by abnormal build-up of two proteins in and around brain cells. Our pipeline targets this pathological protein with precision, aiming to halt its destructive progression and alleviate the debilitating symptoms that rob individuals of their quality of life.
We are also expanding our therapeutic reach to encompass rare neurological diseases such as Adrenoleukodystrophy (ALD) and Adrenoleukomyeloneuropathy (AMN), rare X-linked disorders that disrupt the metabolism of very long-chain fatty acids. Our vectorized gene therapy approach holds the potential to restore normal cellular function and alleviate the devastating neurological consequences of these disorders.
A Targeted Approach to Genomic Therapeutic Targets
Our pipeline of patient-centered interventional genomic therapeutic targets is meticulously designed to harness the power of gene therapy in a personalized and precise manner. Our robust AI-assisted portfolio of neurological disease assets, along with inflammatory disease assets, underscores our commitment to developing transformative therapies.
Pioneering Treatments for Rheumatoid Arthritis
Within our pipeline, we are spearheading groundbreaking research aimed at curing Rheumatoid Arthritis (RA), an autoimmune disorder that causes chronic inflammation and joint damage. Our approach utilizes cutting-edge gene therapy to modulate the immune system and halt the destructive processes underlying RA.
Companion Diagnostics for Early Detection and Intervention
In conjunction with our therapeutic efforts, we are also developing novel companion diagnostics that leverage miRNA biomarkers sourced from partner human clinical trials. These diagnostics hold the potential to detect complex diseases and cancers at their earliest stages, enabling timely intervention and maximizing the efficacy of our therapeutic approaches.
Active Preclinical Studies and Clinical Trials
Our commitment to translating scientific breakthroughs into tangible patient benefits is evident in our active preclinical studies and our commitment to develop clinical trials for targeted therapeutic areas. These studies are paving the way for the development of innovative treatments that offer renewed hope for individuals facing debilitating diseases.
Canary DigiGENE miRNA Diagnostic overview
Our point of care diagnostic platform uses Al to read miRNA expression patterns in complex diseases at the earliest stages.
Studies have shown a clear distinction in miRNA expression patterns between disease sample and normal healthy samples. Below is a heat map of matched the same four breast cancer patients showing separation of miRNA expression profiles in tumors and normal tissues.
Canary Pipeline Overview
Therapeutic Pipeline
Diagnostic Pipeline
How it Works

“Lab-on-a-Chip” with Cloud-based Analytics

DigiGENE™ Molecular Point-of-Care Test Platform

One Step Nucleic Acid Amplification Test